Biomanufacturing

Avantor Named Best Bioprocessing Supplier in Single-Use Manufacturing at Asia-Pacific Bioprocessing Excellence Awards 2021

Tuesday, April 6, 2021 - 5:29am

Singapore, Apr 6, 2021 - (ACN Newswire) - Avantor Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, was named Best Bioprocessing Supplier in Single-Use Manufacturing at the Asia-Pacific Bioprocessing Excellence Awards 2021 held recently.

Key Points: 
  • Singapore, Apr 6, 2021 - (ACN Newswire) - Avantor Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, was named Best Bioprocessing Supplier in Single-Use Manufacturing at the Asia-Pacific Bioprocessing Excellence Awards 2021 held recently.
  • Avantor was also awarded Best Company in Bioprocessing Excellence for Single-use Solutions at Biologics Manufacturing Korea 2020.
  • For information, visit avantorsciences.com and find us on:
    The Asia-Pacific Bioprocessing Excellence Awards seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence with enhanced speed, reduced cost, and superior quality.
  • 2021 marks the fifth year of ABEA, which was first established in 2017 and backed by industry requests.

The Government of Canada makes historic investment to strengthen Canada's biomanufacturing sector

Wednesday, March 31, 2021 - 3:05pm

Today's announcement will not only reinforce Canada's biomanufacturing capacity but also strengthen our country's pandemic preparedness.

Key Points: 
  • Today's announcement will not only reinforce Canada's biomanufacturing capacity but also strengthen our country's pandemic preparedness.
  • This once-in-a-generation investment shows our government's commitment to rebuilding Canada's domestic biomanufacturing sector, focusing on both short-term strategic solutions and a longterm vision.
  • "This major new investment in biomanufacturing is an important step forward for Canada.
  • Thus far, the Government of Canada has invested in ten firms through SIF that accelerate vaccine, therapy and biomanufacturing capacity in Canada.

CASIS Releases Two ISS National Lab Research Announcements For In-Space Production Applications

Monday, March 22, 2021 - 5:01pm

These two in-space production applications research announcements are in the focus areas of: 1) Advanced Manufacturing and Materials and 2) Tissue Engineering and Biomanufacturing.

Key Points: 
  • These two in-space production applications research announcements are in the focus areas of: 1) Advanced Manufacturing and Materials and 2) Tissue Engineering and Biomanufacturing.
  • Advancing in-space production applications onboard the space station has been identified as a strategic priority for both NASA and the ISS National Lab.
  • Through opportunities such as these research announcements, CASIS aims to reach both existing ISS investigators and potential new space station users.
  • ISS National Lab Research Announcement 2021-5: In-Space Production Applications for Advanced Manufacturing and Materials
    Through this research announcement, CASIS seeks proposals in the areas of advanced or exotic materials production and/or associated technologies.

G-CON Manufacturing and Just - Evotec Biologics Complete the Installation of Cleanroom PODs® for the First J.POD® Facility in North America

Tuesday, March 16, 2021 - 2:15pm

The delivery advances the completion of the first J.POD manufacturing facility in North America, a one-of-a-kind cGMP biomanufacturing facility that features small intensified bioprocessing operations housed inside G-CON cleanroom PODs.

Key Points: 
  • The delivery advances the completion of the first J.POD manufacturing facility in North America, a one-of-a-kind cGMP biomanufacturing facility that features small intensified bioprocessing operations housed inside G-CON cleanroom PODs.
  • The news comes just weeks after Evotec's announcement of Just Evotec Biologics' expanded contract with the Department of Defense for the manufacturing of anti-SARS-CoV-2 monoclonal antibodies.
  • Just Evotec Biologics has adopted our cleanroom PODs as an integral component of their manufacturing technology platform and we appreciate their trust."
  • G-CON POD cleanroom units surpass traditional cleanroom structures in scalability, mobility and the possibility of repurposing the PODs once the production process reaches its lifecycle end.

Lygos and the Agile BioFoundry Generate Largest Multi-Omics Dataset to Accelerate Machine Learning Capabilities for Engineering Strains for Producing Organic Acids

Monday, March 15, 2021 - 12:03pm

Together, Lygos and ABF aim to demonstrate a high-throughput engineering cycle that incorporates multi-omics analysis and machine learning with industry-leading cycle times.

Key Points: 
  • Together, Lygos and ABF aim to demonstrate a high-throughput engineering cycle that incorporates multi-omics analysis and machine learning with industry-leading cycle times.
  • The project leverages Lygos expertise in designing, building and cultivating its organic acid yeast strains, as well as its malonic acid biosynthetic pathway.
  • The Agile BioFoundrys objective is to develop and deploy technologies that enable commercially-relevant biomanufacturing, including using advanced machine learning methods in non-model microbes.
  • The Agile BioFoundry is one of nine bioenergy industry consortia funded by the U.S. Department of Energy Bioenergy Technologies Office.

Worldwide Industry for Cell Therapy Biomanufacturing to 2025 - Key Market Trends and Challenges

Tuesday, February 23, 2021 - 9:00pm

This research report presents an in-depth analysis of the global cell therapy biomanufacturing market by product type, application and region.

Key Points: 
  • This research report presents an in-depth analysis of the global cell therapy biomanufacturing market by product type, application and region.
  • The report discusses the key inhibitors to the growth of cell therapy biomanufacturing.
  • The report analyzes key companies operating in the global cell therapy biomanufacturing market.
  • In this report, the cell therapy biomanufacturing market is segmented by product type, application and region.

Global Cell Therapy Biomanufacturing Market (2020 to 2025) - Featuring Lonza Group, Merck & Novartis Among Others - ResearchAndMarkets.com

Thursday, February 18, 2021 - 4:33pm

This research report presents an in-depth analysis of the global cell therapy biomanufacturing market by product type, application and region.

Key Points: 
  • This research report presents an in-depth analysis of the global cell therapy biomanufacturing market by product type, application and region.
  • The report discusses the key inhibitors to the growth of cell therapy biomanufacturing.
  • The report analyzes key companies operating in the global cell therapy biomanufacturing market.
  • In this report, the cell therapy biomanufacturing market is segmented by product type, application and region.

Northway Biotech Opens New Biopharmaceutical Manufacturing Facility in Greater Boston Area

Thursday, January 21, 2021 - 4:18am

From cell line development to cGMP DS manufacturing and aseptic filling, the state-of-the-art facility, in the booming biotech hub in the Greater Boston area, will provide end-to-end services for biologics microbial and mammalian based biologics.

Key Points: 
  • From cell line development to cGMP DS manufacturing and aseptic filling, the state-of-the-art facility, in the booming biotech hub in the Greater Boston area, will provide end-to-end services for biologics microbial and mammalian based biologics.
  • "Northway Biotech reaches an important strategic milestone to further strengthen its leadership by opening a second biomanufacturing facility and its first in the United States.
  • Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide.
  • Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products.

Northway Biotech Opens New Biopharmaceutical Manufacturing Facility in Greater Boston Area

Thursday, January 21, 2021 - 4:05am

From cell line development to cGMP DS manufacturing and aseptic filling, the state-of-the-art facility, in the booming biotech hub in the Greater Boston area, will provide end-to-end services for biologics microbial and mammalian based biologics.

Key Points: 
  • From cell line development to cGMP DS manufacturing and aseptic filling, the state-of-the-art facility, in the booming biotech hub in the Greater Boston area, will provide end-to-end services for biologics microbial and mammalian based biologics.
  • "Northway Biotech reaches an important strategic milestone to further strengthen its leadership by opening a second biomanufacturing facility and its first in the United States.
  • Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide.
  • Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products.

Cytiva delivers modular biologics factory to Lonza

Thursday, January 14, 2021 - 7:00am

The high throughput modular biomanufacturing facility will offer process development and manufacturing for Chinese companies developing innovative medicines, as well as multinationals with manufacturing requirements in China.

Key Points: 
  • The high throughput modular biomanufacturing facility will offer process development and manufacturing for Chinese companies developing innovative medicines, as well as multinationals with manufacturing requirements in China.
  • Olivier Loeillot, Vice President, Cytiva, says: "In a rapidly-growing industry with increasing needs for mAbsand other key biopharmaceuticals,this facility demonstrates the strength of combining modular manufacturing withsingle-use technologies.
  • Guangzhou Biopark is also home to manufacturing sites for BeiGene and Akesobio, where Cytiva also provided solutions.
  • Cytiva has delivered 77 KUBio and FlexFactory solutions to customers around the world.